Department of Gynaecology and Obstetrics, Xijing Hospital, Fourth Military Medical University.
Chem Pharm Bull (Tokyo). 2021;69(4):325-332. doi: 10.1248/cpb.c20-00600.
Chemoresistance is one of the main factors of treatment failure of cervical cancer (CC). Here, we intended to discover the role and mechanism of miR-509-5p in the paclitaxel chemoresistance of CC cells. RT-PCR was conducted to verify miR-509-3p expression. HCC94 and C-33A paclitaxel-resistant CC cell models were constructed. Additionally, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and flow cytometry were performed to verify the viability and apoptosis of HCC94 and C-33A cells after upregulating miR-509-3p. Besides, the downstream target of miR-509-3p was analyzed by bioinformatics, and the targeted relationship between miR-509-3p and RAC1 was identified by the dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay. Further, the expression of apoptotic proteins (Bcl2, Bax, and Caspase3) and the RAC1/PAK1/LIMK1/Cofilin pathway was monitored by Western blot. The result showed that upregulating miR-509-3p markedly inhibited the viability and promoted the apoptosis of CC cells. On the other hand, miR-509-3p was distinctly downregulated in paclitaxel-resistant HCC94 and C-33A cells (vs. normal cells). The transfection of miR-509-3p mimics notably increased their sensitivity to paclitaxel. Meanwhile, RAC1 was found as the potential target of miR-509-3p in bioinformatics analysis. Moreover, the RAC1/p21 (RAC1) activated kinase 1 (PAK1)/LIM kinase 1 (LIMK1)/Cofilin pathway was significantly activated in paclitaxel-resistant HCC94 and C-33A cells, while miR-509-3p overexpression significantly inactivated this pathway. Additionally, downregulation of RAC1 also partly reversed the paclitaxel-resistance of CC cells and inhibited PAK1/LIMK1/Cofilin. All in all, miR-509-3p enhances the apoptosis and chemosensitivity of CC cells by regulating the RAC1/PAK1/LIMK1/Cofilin pathway.
化学耐药性是宫颈癌 (CC) 治疗失败的主要因素之一。在这里,我们旨在发现 miR-509-5p 在 CC 细胞紫杉醇耐药中的作用和机制。通过 RT-PCR 验证 miR-509-3p 的表达。构建 HCC94 和 C-33A 紫杉醇耐药 CC 细胞模型。此外,通过 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐 (MTT) 测定和流式细胞术验证上调 miR-509-3p 后 HCC94 和 C-33A 细胞的活力和凋亡。此外,通过生物信息学分析 miR-509-3p 的下游靶标,并通过双荧光素酶报告基因测定和 RNA 免疫沉淀 (RIP) 测定鉴定 miR-509-3p 与 RAC1 的靶向关系。进一步通过 Western blot 监测凋亡蛋白 (Bcl2、Bax 和 Caspase3) 和 RAC1/PAK1/LIMK1/Cofilin 通路的表达。结果表明,上调 miR-509-3p 显著抑制 CC 细胞的活力并促进其凋亡。另一方面,miR-509-3p 在紫杉醇耐药的 HCC94 和 C-33A 细胞中明显下调 (与正常细胞相比)。miR-509-3p 模拟物的转染显著增加了它们对紫杉醇的敏感性。同时,生物信息学分析发现 RAC1 是 miR-509-3p 的潜在靶标。此外,在紫杉醇耐药的 HCC94 和 C-33A 细胞中,RAC1/丝裂原活化蛋白激酶 1 (PAK1)/LIM 激酶 1 (LIMK1)/Cofilin 通路明显激活,而过表达 miR-509-3p 则显著抑制该通路。此外,下调 RAC1 也部分逆转了 CC 细胞的紫杉醇耐药性并抑制了 PAK1/LIMK1/Cofilin。总之,miR-509-3p 通过调节 RAC1/PAK1/LIMK1/Cofilin 通路增强 CC 细胞的凋亡和化疗敏感性。